Preventing diabetes complications

被引:3
|
作者
Templer, Sophie [1 ,2 ]
Abdo, Sarah [1 ,3 ]
Wong, Tang [1 ,2 ,3 ]
机构
[1] Bankstown Lidcombe Hosp, Dept Endocrinol, Sydney, NSW, Australia
[2] Univ New South Wales, Fac Med, Sydney, NSW, Australia
[3] Western Sydney Univ, Sch Med, Sydney, NSW, Australia
关键词
diabetes; macrovascular complications; microvascular complications; cardiovascular disease; glycaemic control; INTENSIVE GLUCOSE CONTROL; CARDIOVASCULAR OUTCOMES; MICROVASCULAR OUTCOMES; INSULIN-TREATMENT; TYPE-2; MORTALITY; DISEASE; METAANALYSIS; MANAGEMENT; MELLITUS;
D O I
10.1111/imj.16455
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The key aim of diabetes management is to prevent complications, which are a major cause of morbidity and mortality. At an individual level, people with diabetes are less likely than they were several decades ago to experience classical macrovascular and microvascular complications as a result of improvements in modifiable cardiovascular risk factors and preventive healthcare. However, a significant burden of diabetes complications persists at a population level because of the increasing incidence of diabetes, as well as longer lifetime exposure to diabetes because of younger diagnosis and increased life expectancy. Trials have shown that the most effective strategy for preventing complications of diabetes is a multifactorial approach focussing simultaneously on the management of diet, exercise, glucose levels, blood pressure and lipids. In addition to the cornerstone strategies of addressing diet, exercise and lifestyle measures, the introduction of newer glucose-lowering agents, including sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 agonists, have brought about a paradigm shift in preventing the onset and progression of complications of type 2 diabetes, particularly cardiovascular and renal disease. The improvement in rates of classical complications of diabetes over time has been accompanied by a growing awareness of non-traditional complications, including non-alcoholic fatty liver disease. These emerging complications may not respond to a glycaemic-centred approach alone and highlight the importance of foundational strategies centred on lifestyle measures and supported by pharmaceutical therapy to achieve weight loss and reduce metabolic risk in patients living with diabetes.
引用
收藏
页码:1264 / 1274
页数:11
相关论文
共 50 条
  • [1] The association of depressive symptoms and diabetes distress with glycaemic control and diabetes complications over 2 years in newly diagnosed type 2 diabetes: a prospective cohort study
    Ismail, Khalida
    Moulton, Calum D.
    Winkley, Kirsty
    Pickup, John C.
    Thomas, Stephen M.
    Sherwood, Roy A.
    Stahl, Daniel
    Amiel, Stephanie A.
    DIABETOLOGIA, 2017, 60 (10) : 2092 - 2102
  • [2] Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications
    Dal Canto, Elisa
    Ceriello, Antonio
    Ryden, Lars
    Ferrini, Marc
    Hansen, Tina B.
    Schnell, Oliver
    Standl, Eberhard
    Beulens, Joline W. J.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2019, 26 (2_SUPPL) : 25 - 32
  • [3] Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)
    Kosiborod, Mikhail
    Gomes, Marilia B.
    Nicolucci, Antonio
    Pocock, Stuart
    Rathmann, Wolfgang
    Shestakova, Marina V.
    Watada, Hirotaka
    Shimomura, Iichiro
    Chen, Hungta
    Cid-Ruzafa, Javier
    Fenici, Peter
    Hammar, Niklas
    Surmont, Filip
    Tang, Fengming
    Khunti, Kamlesh
    CARDIOVASCULAR DIABETOLOGY, 2018, 17
  • [4] Real-World Data on the Incidence of Macrovascular Complications in Japanese Patients with Type 2 Diabetes: The Sitagliptin Registration Type 2 Diabetes-Juntendo Collaborating Project
    Ohmura, Hirotoshi
    Mita, Tomoya
    Matsuoka, Joe
    Nojiri, Shuko
    Nishizaki, Yuji
    Watada, Hirotaka
    Daida, Hiroyuki
    DIABETES THERAPY, 2019, 10 (03) : 1099 - 1111
  • [5] Weight variability and diabetes complications
    Prattichizzo, Francesco
    Frige, Chiara
    La Grotta, Rosalba
    Ceriello, Antonio
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 199
  • [6] The effect of guideline revisions on vascular complications of type 2 diabetes
    Heijmans, Ralph
    Singh, Sunny S.
    Lieverse, Aloysius G.
    Sijbrands, Eric J. G.
    van Hoek, Mandy
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2019, 10
  • [7] Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes
    Zoungas, Sophia
    Woodward, Mark
    Li, Qiang
    Cooper, Mark E.
    Hamet, Pavel
    Harrap, Stephen
    Heller, Simon
    Marre, Michel
    Patel, Anushka
    Poulter, Neil
    Williams, Bryan
    Chalmers, John
    DIABETOLOGIA, 2014, 57 (12) : 2465 - 2474
  • [8] The patient with diabetes: Preventing cardiovascular complications
    Heinig, Robert E.
    CLINICAL CARDIOLOGY, 2006, 29 (10) : 13 - 20
  • [9] Metabolic health and vascular complications in type 1 diabetes
    Bhattarai, Sandhya
    Godsland, Ian F.
    Misra, Shivani
    Johnston, Desmond G.
    Oliver, Nick
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2019, 33 (09) : 634 - 640
  • [10] Prevalence of macro- and microvascular complications among patients with type 2 diabetes in Iran: A systematic review
    Amini, Masoud
    Parvaresh, Ehsan
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2009, 83 (01) : 18 - 25